P2Y12 Receptor Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndrome Patients: An Assessment of Current Evidence

Published: 23 February 2021

  • Views:

    Views Icon 32763
  • Likes:

    Heart Icon 11

Overview

Full programme

  • Views:

    Views Icon 32763
  • Likes:

    Heart Icon 11

Overview

A roundtable to discuss the current evidence for P2Y12 inhibitor use in NSTE-ACS

The European Heart Association’s guideline update on NSTE-ACS management in 2020 took into consideration several landmark trials, which ultimately changed the level of recommendation on key aspects of antiplatelet use, in both pre- and post-PCI practice. This roundtable, led by Prof Dominick Angiolillo, considers the main updates, the data underpinning the changes and what they mean for real-world practice through expert discourse and case examination.

 

*Submit your questions to the faculty by clicking on the 'Q&A' button to the right of the screen. Your questions will be answered by the faculty and shared as a final chapter of the NSTEMI roundtable. 

This independent medical education programme is supported by an unrestricted educational grant from AstraZeneca. AstraZeneca has no involvement in the organisation of the programme.

Learning Objectives

  • Recall the supportive evidence underpinning recommended antiplatelet approaches in individuals with unknown coronary anatomy, including choice of therapy, duration, timing and loading doses
  • Compare the design of different clinical trials that have influenced antiplatelet therapy choice in NSTE-ACS patients who proceed to PCI
  • Apply trial data and clinical guidelines on the use of antiplatelet therapy in patients undergoing revascularisation to a surrogate patient case

Series overview

Part 1

Chapter 1

Here, the faculty will provide an overview of recent changes to ESC guidelines on P2Y12 treatment pre- and post-intervention.

Part 2

Chapter 2

In this chapter the faculty review clinical data that have shaped current ESC recommendations. The faculty describe pivotal trials including PLATO, TRITON-TIMI, ACCOAST and ISAR-REACT 5.

Part 3

Chapter 3

In this chapter the faculty hold an open discussion on new recommendations around pre-treatment and choice of agent.

Part 4

Chapter 4

In this chapter, Prof Angiolillo presents hypothetical cases for the faculty to discuss.

Part 5

Chapter 5

In this final chapter, the faculty will review and answer the questions asked by the viewers.
1 session
Q&A Watch now

Faculty Biographies

Dominick J Angiolillo

Dominick J Angiolillo

Professor

Dr Dominick Angiolillo graduated from the Catholic University of the Sacred Heart Medical School in Rome, Italy and pursued training in interventional cardiology at the Complutense University of Madrid in Spain and received his Ph.D. in cellular and molecular cardiology. 

In 2004, Dr Angiolillo joined the University of Florida College of Medicine – Jacksonville, where he is a professor of medicine, director of cardiovascular research and director of the interventional cardiology fellowship program. 

Dr Angiolillo has made major scientific contributions to many medical and cardiovascular journals, as well as cardiovascular medicine textbooks. He has authored more than 400 peer-reviewed articles, with nearly 30,000 citations and an H-index of 86. He has authored more than 30 book chapters and is the editor of his own textbook on antithrombotic medicine.

Dr Dominick J Angiolillo is on the Editorial Board of European Cardiology Review.

View full profile
Robert F Storey

Robert F Storey

Professor and Honorary Consultant in Cardiology

Prof. Storey is Academic Director and an honorary Consultant Cardiologist for the Cardiology and Cardiothoracic Surgery Directorate, Sheffield Teaching Hospitals NHS Foundation Trust. He is Professor of Cardiology at the University of Sheffield, UK, where he has headed a platelet research group since 2002 within the Department of Cardiovascular Science.

He has a special interest in the management of ischaemic heart disease, including acute coronary syndromes and coronary intervention. He served as a member of the executive committees for the PLATO and PEGASUS studies, leading the platelet function substudies for these trials, and of the steering committee for the TRA-CER, EPICOR and ATLANTIC studies. He is currently a member of the steering committee for the COMPLETE study. He was Chair of the Working Group on Thrombosis of the European Society of Cardiology (ESC) from 2012-2014 and has been a Task Force member for several ESC guidelines on non-ST-elevation acute coronary…

View full profile
Roxana Mehran

Roxana Mehran

Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, FSCAI is Professor of Medicine and Director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A Weiner Cardiovascular Institute at Mount Sinai School of Medicine.

Prof Mehran is Professor of Medicine, Cardiology and Professor of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai in New York. She is also Director of Interventional Cardiovascular Research and Clinical Trials at The Zena and Michael A Weiner Cardiovascular Institute at Mount Sinai Hospital where, over the past 5 years, she has led the development of a globally respected data and clinical coordination centre to support large, multicentre, multinational clinical trials designed to help improve outcomes and quality of life for patients undergoing interventional cardiovascular procedures. In recent years, her work has had a special emphasis on gaining a deeper understanding of anticoagulation and…

View full profile
Gilles Montalescot

Gilles Montalescot

Hospitalier Universitaire Pitié-Salpêtrière, Paris, France

View full profile